127-33-3 Usage
Uses
Used in Medical Applications:
Demeclocycline is used as an antibiotic for the treatment of various conditions, including Lyme disease, acne, and bronchitis. It is also utilized for the management of hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) when fluid restriction alone has been ineffective.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, demeclocycline is used as an active pharmaceutical ingredient, mainly in the form of its hydrochloride salt. It is marketed under the brand name Declomycin (Lederle) and is extensively cited in the literature with over 800 references, primarily focusing on its in vivo use.
Originator
Declomycin,Lederle,US,1959
Manufacturing Process
According to US Patent 2,878,289, a suitable medium for the preparation of
inocula for the fermentation may be prepared with the following substances.The pH of the medium thus prepared is about 6.8. An 8 ml portion is
measured into an 8 inch Brewer tube and sterilized at 120°C for 20 minutes.
The sterilized medium is then inoculated with 0.5 ml of an aqueous spore
suspension of a strain of S. aureofaciens capable of producing
chlorodemethyltetracycline, such as S-604, containing approximately 40-60
million spores per milliliter. The inoculated medium is incubated for 24 hours
at 28°C on a reciprocating shaker operated at 110 cycles per minute.A suitable fermentation medium contains water and a source of assimilable
carbon and nitrogen and essential mineral salts. A typical medium suitable for
production of chlorodemethyltetracycline is as follows:A suitable fermentation medium contains water and a source of assimilable
carbon and nitrogen and essential mineral salts. A typical medium suitable for
production of chlorodemethyltetracycline is as follows:Ten percent of the resulting inoculum is then transferred to a 250 ml
Erlenmeyer flask containing 50 ml of the medium employed above and the
flask agitated a further 72 hours under the same conditions. One ml of the
resulting inoculum is then employed for the inoculation of 10 ml of an
aqueous medium containing, per 1,000 ml, 30 grams extraction process
soybean meal, 1 gram sodium chloride, 50 grams glucose and 7 grams
calcium carbonate, in a 1" x 6" test tube.In addition, 1 mg of sterile S-2-hydroxyethyl-DL-homocysteine is added to the
tube and the tube is shaken on a rotary shaker at 280 cycles per minute at
25°C for seven days. The contents of the tube were then acidified to pH 2 by
the addition of sulfuric acid and centrifuged. Examination of the supernatant
liquid by paper chromatography employing the methods of Bohonos et al,
Antibiotics Annual (1953-4, page 49),demonstrates the presence of 7-chloro6-demethyltetracycline,7-chlorotetracycline and tetracycline.
Therapeutic Function
Antibacterial
Safety Profile
Poison by intravenous
and intraperitoneal routes. Human systemic
effects by ingestion: diabetes insipidus, urine
volume increase, other changes in urine
composition, dermatitis, changes in the
nails, allergic rhinitis, serum sickness, effects
on cyclic nucleotides. Human reproductive
effects by an unspecified route: postnatal
measures or effects on newborn. An
experimental teratogen. Experimental
reproductive effects. Human mutation data
reported. When heated to decomposition it
emits very toxic fumes of Cland NOx.
Check Digit Verification of cas no
The CAS Registry Mumber 127-33-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 1,2 and 7 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 127-33:
(5*1)+(4*2)+(3*7)+(2*3)+(1*3)=43
43 % 10 = 3
So 127-33-3 is a valid CAS Registry Number.
InChI:InChI=1/C21H21ClN2O8.ClH/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31;/h3-4,6-7,14-15,25-26,28-29,32H,5H2,1-2H3,(H2,23,31);1H/t6-,7-,14-,15-,21-;/m0./s1
127-33-3Relevant articles and documents
Compositions and methods for treating hemorrhagic virus infections and other disorders
-
, (2008/06/13)
Cytokine-receptor and cytokine antagonist-enriched blood-dervided compositions and methods of preparing and using the compositions are provided. Also provided are compositions and methods for the treatment or prevention of disorders, especially acute inflammatory disorders involving pathological responses of the immune system, such as viral hemorrhagic diseases, sepsis, rheumatoid arthritis and other autoimmune disorders, acute cardiovascular events, flare-ups and acute phases of multiple sclerosis, wasting disorders and other disorders involving deleterious expression of cytokines and other factors, including tumor necrosis factor (TNF) and interleukin-1 (IL-1) are provided.
